Twenty years after opening, the H. Lee Moffitt Cancer Center &Research Institute is submitting its second competitive renewal application for its Cancer Center Support Grant for grant years 10 through 14. The Center's mission remains solely focused on """"""""contributing to the prevention and cure of cancer."""""""" The Moffitt Cancer Center, a freestanding, not-for-profit corporation located on the University of South Florida campus in Tampa, Florida, includes a research institute coupled with a 162-bed inpatient facility, an active outpatient clinic with more than 200,000 patient visits per year, a high-risk screening and prevention center, a dedicated Clinical Research Unit for early phase studies, an affiliate network of Florida hospitals and oncology practices and a wide array of outreach and educational activities. The Cancer Center has five scientific programs, all with a translational focus;14 shared resources (five newly proposed), and a research infrastructure that supports innovative, translational research and enhances interactions among basic scientists, population-based scientists and clinical investigators. Research programs include Molecular Oncology &Drug Discovery, Immunology, Experimental Therapeutics, Risk Assessment, Detection &Intervention, and Health Outcomes &Behavior. Shared resources include Flow Cytometry, Molecular Biology, Microarray, Proteomics, High Throughput Screening &Chemistry, Mouse Models, Analytic Microscopy, Tissue, Cell Therapies, Survey Methods, Informatics, Biostatistics, Clinical Research Support Services and the Clinical Trials Laboratory Core. The Protocol Review &Monitoring System includes two Scientific Review Committees and a separate Protocol Monitoring Committee. Protocol specific support for a large-volume early phase clinical trial portfolio is also requested. During the period since designation as an NCI Comprehensive Cancer Center and the current CCSG submission (2001-2006), the Center has more than doubled its peer reviewed funding and increased NCI funding from $10.6 million to $29 million total dollars;increased accrual to phase I investigator-authored clinical trials from 130 to 534 annually and enrollment on all trials to more than 6,000;opened the Stabile Research Building to nearly double available research space;and created a network of 16 affiliate hospitals and 380 physicians throughout Florida. The Center's 135 members collaborate extensively with 25% of total publications being inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-11S5
Application #
7934869
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2009-09-01
Project End
2012-08-31
Budget Start
2009-09-01
Budget End
2012-08-31
Support Year
11
Fiscal Year
2009
Total Cost
$1,123,929
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459

Showing the most recent 10 out of 1254 publications